6622 (6622) Fair Value & Analysis

Healthcare · Market cap HK$1.4B

6 6622 6622 · HK

PriceHK$2.58

Fair ValueHK$1.75

Upside-32.2%

Quality40/100

Watch 6622 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$1.16 – HK$2.19

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price −0.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$2.40 – HK$4.45 · fair‑value band HK$1.16 – HK$2.19 · the HK$2.58 price screens above the HK$1.75 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

6622 (6622) currently trades at HK$2.58, while our model-based Fair Value estimate is HK$1.75 — implying the stock looks roughly 32.2% overvalued today. We read business quality at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Trailing-twelve-month revenue stands at HK$32.0M. Revenue declined 17.3% year over year. It earns a return on equity of -12.0%. The balance sheet holds a net cash position of HK$1.0B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$32.0M

Revenue growth (YoY) -17.3%

Return on equity -12.0%

Free cash flow −HK$265M FY2025

Operating margin -708%

EPS (TTM) HK$-0.2100

More key figures

Net cash HK$1.0B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

6622 reported revenue of HK$31.1M in FY2025 versus HK$0 in FY2021. Reported net income was −HK$204M in FY2025.

Revenue

FY21 HK$0

FY22 HK$0

FY23 HK$18.8M

FY24 HK$69.3M

FY25 HK$31.1M

Net income

FY21 −HK$2.1B

FY22 −HK$407M

FY23 −HK$385M

FY24 −HK$237M

FY25 −HK$204M

Is 6622 fairly valued? → Check now

Similar stocks

6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	7,746 MXN	4,803 MXN	-38%
Regeneron Pharmaceuticals, Inc REGN	$635.45	$547.01	-14%
UCB SA UCB	€274.90	€211.40	-23%
argenx SE ARGNF	$900.00	$382.64	-57%
Alnylam Pharmaceuticals, Inc ALNY	$291.22	$111.44	-62%
Samsung Biologics Co 207940	1,000,000 KRW	1,011,109 KRW	+1%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 6622 (6622) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$1.75 versus a price of HK$2.58 — about −32% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 6622?

Our model-based fair value for 6622 is HK$1.75 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$2.58.

What is the quality score of 6622?

6622 has a Quality Score of 40/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 6622 (6622)?

6622 reported trailing-twelve-month revenue of about HK$32.0M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 6622?

The net profit margin of 6622 is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.